Multiple System Atrophy, Neurogenic orthostatic hypotension
TBPHTheravance BiopharmaCatalyst overview
Research summary
This catalyst tracks a Failed discontinued for Ampreloxetine (TD-9855) in Multiple System Atrophy, Neurogenic orthostatic hypotension. The expected timing is based on the latest available company guidance and may change.
CYPRESS study. 5/9/25- Multiple data presentations at MSA Cong. '25. 8/12/25- Final patient enrollment into the study by late summer; topline data ~6 months later. 8/25/25- Completed enrollment; topline results in Q1 2026. 11/10/25:- Open-label Ph3 CYPRESS portion complete; topline results remain on track Q1 2026; KOL event Dec 8, 2025. 03/03/26:- Ph3 CYPRESS topline missed primary endpoint; company will wind down ampreloxetine program.
Verification
Confirm timing and program details against the company announcement or filing.